RNASE2 and myeloid sarcoma: In this study, we found that RNASE2 is a common immune- and metabolism-related biomarker for both MS and IPAH, which suggests that RNASE2 may be responsible for the development of metabolic disorders in both diseases, proving it has an important potential role in diagnosing MS patients with IPAH.